Welcome to our dedicated page for Elicio Therapeutics news (Ticker: $ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Elicio Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Elicio Therapeutics's position in the market.
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced promising results from the Phase 1 study of ELI-002 in Nature Medicine, demonstrating robust, polyfunctional, and durable KRAS-specific CD4+ and CD8+ T cell responses in cancer patients. The study showed an 84% reduction in tumor biomarkers, correlating with a median relapse-free survival of 16.3 months. A Phase 2 trial for ELI-002 in pancreatic ductal adenocarcinoma is planned to start in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.31%
Tags
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) has entered into a subscription agreement to sell 1,213,000 shares of its common stock at a purchase price of $5.81 per share in a private placement to GKCC, LLC, controlled by a member of Elicio’s Board of Directors. The gross proceeds of the private placement are expected to be approximately $7.0 million, with the net proceeds intended for the advancement of its development pipeline, as well as for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.21%
Tags
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) will present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023. The company is a clinical-stage biotechnology firm focusing on developing immunotherapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.04%
Tags
News
Rhea-AI Summary
ELTX: Elicio Therapeutics reports promising results for ELI-002 in pancreatic cancer treatment. Median relapse-free survival of 16.3 months and a significant reduction in risk of progression or death. Plans to initiate ELI-002 7P Phase 2 trial in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
-
Rhea-AI Summary
Elicio Therapeutics announces promising data from the Phase 1 study of ELI-002 cancer vaccine in patients with mKRAS-driven pancreatic and colorectal cancers. 87% of patients had mKRAS-specific T cell responses and the strength of the response correlated with reduced risk of relapse and death. ELI-007 and ELI-008 vaccines also showed strong induction of tumor-antigen-specific T cell responses in mice.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Elicio Therapeutics to present updated data on ELI-002 and preclinical data on ELI-007 and ELI-008 at SITC 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
Rhea-AI Summary
Elicio Therapeutics announces promising preliminary relapse-free survival data for its cancer vaccine ELI-002. Preliminary data from the Phase 1 study shows an 86% reduction in the risk of progression or death in patients with large T cell responses. Elicio plans to initiate a randomized Phase 2 study in early 2024. No safety concerns were identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
-
Rhea-AI Summary
Elicio Therapeutics receives $2.6M grant for cancer vaccine research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
-
Rhea-AI Summary
Elicio Therapeutics to present at H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
Rhea-AI Summary
Elicio Therapeutics to present additional data on ELI-002 in pancreatic cancer study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.46%
Tags
Elicio Therapeutics, Inc.
Nasdaq:ELTX
ELTX Rankings
ELTX Stock Data
91.88M
5.39M
45.06%
5.31%
0.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
BOSTON
About ELTX
elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. by combining expertise in materials science and immunology, elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. the elicio amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body’s own system of defenses, to defeat cancer and stop its recurrence. this substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. elicio's lead amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. elicio was founded to expand and apply the ground-breaking amphiphile technology invented and developed in the labs of darrell